Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Psychiatry (24)
- Schizophrenia (14)
- Psychosis (8)
- Depression (6)
- Suicide (6)
-
- Mumbai (4)
- Risk assessment (3)
- Antidepressant (2)
- Cannabis (2)
- Catatonia (2)
- Clinical assessment (2)
- Instrument (2)
- Risk (2)
- Schizoaffective disorder (2)
- Antipsychotic drug (1)
- Antipsychotic drugs (1)
- Assessment (1)
- Atypical antipsychotic (1)
- Clinical interview (1)
- Clinical psychiatry (1)
- Cognition (1)
- Cognitive enhancement (1)
- Comorbidity (1)
- Crisis (1)
- Diagnosis (1)
- Early intervention (1)
- Global Mental health (1)
- Mental health (1)
- Mood symptoms (1)
- Outcome measures (1)
Articles 1 - 30 of 33
Full-Text Articles in Entire DC Network
Clinical Interview For Psychiatric Assessment, Amresh Srivastava
Clinical Interview For Psychiatric Assessment, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Early Psychosis: A Novel Gateway For Suicide Prevention, Amresh Srivastava
Early Psychosis: A Novel Gateway For Suicide Prevention, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Family Education For Psychosis, Amresh Srivastava
Family Education For Psychosis, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Cannabis & Psychosis: The Interface Emerging Frontiers For Research, Amresh Shrivastava
Cannabis & Psychosis: The Interface Emerging Frontiers For Research, Amresh Shrivastava
Amresh Srivastava
INTRODUCTION: CANNABIS CONTINUES TO AFFECT MENTAL HEALTH. ITS ABUSE IS ON RISE GLOBALLY. IN CANADA A RISE BY 30% IN LAST TEN YEARS HAS BEEN OBSERVED IN HIGH SCHOOL STUDENTS. INTERRELATIONSHIP OF CANNABIS WITH PSYCHOSIS AND SCHIZOPHRENIA IS A COMPLEX ONE. CANNABIS IS HIGHLY COMORBID WITH PSYCHOSIS, & RELATED TO FUNCTIONAL DISABILITY AND OUTCOME. IT POSES SEVERAL CHALLENGES IN UNDERSTANDING CAUSAL RELATIONSHIP FOR COMORBIDITY, UNDERLYING NEUROCHEMICAL BASIS AND SPECIFICS OF SERVICE DEVELOPMENT. PREVALENCE OF CANNABIS VARIES FROM 20 TO 50% EARLY PSYCHOSIS. OBJECTIVE OF THIS PAPER IS TO REVIEW AVAILABLE LITERATURE TO IDENTIFY CHALLENGES FOR NEWER TARGETS OF RESEARCH AND …
Response, Remission & Recovery: Need To Review Outcome Measures For Schizophrenia, Amresh Shrivastava, Nilesh Shah
Response, Remission & Recovery: Need To Review Outcome Measures For Schizophrenia, Amresh Shrivastava, Nilesh Shah
Amresh Srivastava
Schizophrenia is a complex neurobehavioral disorder known to be associated with poor outcome. It causes significant disability in patients and burden of care amongst relatives. Outcome in developing countries has been reported to be far better than western world, which has come into scientific scanner recently. Wide gap exists between expectations of outcome amongst patients, relatives, caregivers and professionals, which is possibly because of limitations in measurements tools. Significant number of patients remain marginalized without improvement in social & occupational functioning preventing their integration into mainstream of society despite 'clinically reported good outcome' and significant advancement in treatments. The contemporary …
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Treatment Resistant Depression, Amresh Srivastava
Treatment Resistant Depression, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Schizophrenia: General Findings And Current Status, Amresh Srivastava
Schizophrenia: General Findings And Current Status, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson
Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson
Amresh Srivastava
No abstract provided.
Switching And Selecting Atypical Antipsychotic Drugs: Paliperidone, Amresh Srivastava
Switching And Selecting Atypical Antipsychotic Drugs: Paliperidone, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava
Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava
Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava
Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson
Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson
Amresh Srivastava
No abstract provided.
Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava
Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Schizophrenia: General Findings And Current Status, Amresh Srivastava
Schizophrenia: General Findings And Current Status, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Relapse Prevention In Schizophrenia, Amresh Srivastava
Relapse Prevention In Schizophrenia, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava
Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava
Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Amresh Srivastava
No abstract provided.
Coping Up Challenges Of Risk Assessment: Towards A New Scale: Sis-Map, Amresh Srivastava, Charles Nelson
Coping Up Challenges Of Risk Assessment: Towards A New Scale: Sis-Map, Amresh Srivastava, Charles Nelson
Amresh Srivastava
No abstract provided.
Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt
Amresh Srivastava
No abstract provided.
Complexity And Limitations Of Stress-Endocrine Research In Mental Health, Amresh Srivastava
Complexity And Limitations Of Stress-Endocrine Research In Mental Health, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Amresh Srivastava
No abstract provided.
Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava
Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava
Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava
Amresh Srivastava
Introduction: cannabis continues to affect mental health. Its abuse is on rise globally. In Canada a rise by 30% in last ten years has been observed in high school students. Interrelationship of cannabis with psychosis and schizophrenia is a complex one. Cannabis is highly comorbid with psychosis, & related to functional disability and outcome. It poses several challenges in understanding causal relationship for comorbidity, underlying neurochemical basis and specifics of service development. Prevalence of Cannabis varies from 20 to 50% early psychosis. Objective of this paper is to review available literature to identify challenges for newer targets of research and …
Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava
Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava
Amresh Srivastava
No abstract provided.
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava
Amresh Srivastava
No abstract provided.
Assessment In Crisis, Amresh Srivastava